PTIP associates with artemis to dictate DNA repair pathway choice

Genes and Development

Volumn 28, Issue 24, 2014, Pages 2693-2698

  Wang, Jiadong ^a,b   Aroumougame, Asaithamby ^c   Lobrich, Markus ^d   Li, Yujing ^b   Chen, David ^c   Chenj, Junjie ^b   Gong, Zihua ^b  

^a PEKING UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

53BP1; Artemis; BRCA1; DNA repair; PARP inhibition; PTIP

Indexed keywords

53BP1 PROTEIN; ADAPTOR PROTEIN; ARTEMIS NUCLEASE; BINDING PROTEIN; BRCA1 PROTEIN; HISTONE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; CARRIER PROTEIN; DCLRE1C PROTEIN, HUMAN; NUCLEAR PROTEIN; PAXIP1 PROTEIN, HUMAN; PROTEIN BINDING; SIGNAL PEPTIDE; TP53BP1 PROTEIN, HUMAN;

ARTICLE; DELETION MUTANT; DNA DAMAGE; DNA END JOINING REPAIR; DNA STRAND BREAKAGE; ENZYME ACTIVITY; IN VITRO STUDY; RECOMBINATION REPAIR; TRANSCRIPTION REGULATION; DNA REPAIR; GENE INACTIVATION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

CARRIER PROTEINS; DNA REPAIR; GENE KNOCKOUT TECHNIQUES; HEK293 CELLS; HELA CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 84918555933     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.252478.114     Document Type: Article

References (30)

1. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376: 245–251.
2. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, et al. 2010. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 17: 688–695.
3. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. 2005. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913–917.
4. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, et al. 2010. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141: 243–254.
5. Callen E, Di Virgilio M, Kruhlak MJ, Nieto-Soler M, Wong N, Chen HT, Faryabi RB, Polato F, Santos M, Starnes LM, et al. 2013. 53BP1 mediates productive and mutagenic DNA repair through distinct phosphoprotein interactions. Cell 153: 1266–1280.
6. Cattell E, Sengerova B, McHugh PJ. 2010. The SNM1/Pso2 family of ICL repair nucleases: from yeast to man. Environ Mol Mutagen 51: 635– 645.
7. Chan SL, Mok T. 2010. PARP inhibition in BRCA-mutated breast and ovarian cancers. Lancet 376: 211–213.
8. Chapman JR, Taylor MR, Boulton SJ. 2012. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell 47: 497–510.
9. Chapman JR, Barral P, Vannier JB, Borel V, Steger M, Tomas-Loba A, Sartori AA, Adams IR, Batista FD, Boulton SJ. 2013. RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection. Mol Cell 49: 858–871.
10. Cho YW, Hong T, Hong S, Guo H, Yu H, Kim D, Guszczynski T, Dressler GR, Copeland TD, Kalkum M, et al. 2007. PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex. J Biol Chem 282: 20395–20406.
11. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819–823.
12. Di Virgilio M, Callen E, Yamane A, Zhang W, Jankovic M, Gitlin AD, Feldhahn N, Resch W, Oliveira TY, Chait BT, et al. 2013. Rif1 prevents resection of DNA breaks and promotes immunoglobulin class switching. Science 339: 711–715.
13. Escribano-Diaz C, Orthwein A, Fradet-Turcotte A, Xing M, Young JT, Tkáačc J, Cook MA, Rosebrock AP, Munro M, Canny MD, et al. 2013. A cell cycle-dependent regulatory circuit composed of 53BP1–RIF1 and BRCA1–CtIP controls DNA repair pathway choice. Mol Cell 49: 872–883.
14. Feng L, Fong KW, Wang J, Wang W, Chen J. 2013. RIF1 counteracts BRCA1-mediated end resection during DNA repair. J Biol Chem 288: 11135–11143.
15. Gong Z, Cho YW, Kim JE, Ge K, Chen J. 2009. Accumulation of Pax2 transactivation domain interaction protein (PTIP) at sites of DNA breaks via RNF8-dependent pathway is required for cell survival after DNA damage. J Biol Chem 284: 7284–7293.
16. Gong Z, Kim JE, Leung CC, Glover JN, Chen J. 2010. BACH1/FANCJ acts with TopBP1 and participates early in DNA replication checkpoint control. Mol Cell 37: 438–446.
17. Goodarzi AA, Yu Y, Riballo E, Douglas P, Walker SA, Ye R, Harer C, Marchetti C, Morrice N, Jeggo PA, et al. 2006. DNA-PK autophosphorylation facilitates Artemis endonuclease activity. EMBO J 25: 3880–3889.
18. Jaspers, JE, Kersbergen, A, Boon, U, Sol, W, van Deemter, L, Zander, SA, Drost, R, Wientjens, E, Ji, J, Aly, A, et al. (2013). Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 3: 68–81.
19. Ma Y, Pannicke U, Schwarz K, Lieber MR. 2002. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 108: 781–794.
20. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. 2013. RNA-guided human genome engineering via Cas9. Science 339: 823–826.
21. Manke IA, Lowery DM, Nguyen A, Yaffe MB. 2003. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 302: 636–639.
22. Moshous D, Callebaut I, de Chasseval R, Corneo B, Cavazzana-Calvo M, Le Deist F, Tezcan I, Sanal O, Bertrand Y, Philippe N et al. 2001. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 105: 177–186.
23. Munoz IM, Jowsey PA, Toth R, Rouse J. 2007. Phospho-epitope binding by the BRCT domains of hPTIP controls multiple aspects of the cellular response to DNA damage. Nucleic Acids Res 35: 5312–5322.
24. Patel SR, Kim D, Levitan I, Dressler GR. 2007. The BRCT-domain containing protein PTIP links PAX2 to a histone H3, lysine 4 methyltransferase complex. Dev Cell 13: 580–592.
25. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235–244.
26. Uematsu N, Weterings E, Yano K, Morotomi-Yano K, Jakob B, Taucher-Scholz G, Mari PO, van Gent DC, Chen BP, Chen DJ. 2007. Autophosphorylation of DNA-PKCS regulates its dynamics at DNA double-strand breaks. J Cell Biol 177: 219–229.
27. Wang J, Gong Z, Chen J. 2011. MDC1 collaborates with TopBP1 in DNA replication checkpoint control. J Cell Biol 193: 267–273.
28. Wang J, Chen J, Gong Z. 2013. TopBP1 controls BLM protein level to maintain genome stability. Mol Cell 52: 667–678.
29. Yu X, Chini CC, He M, Mer G, Chen J. 2003. The BRCT domain is a phospho-protein binding domain. Science 302: 639–642.
30. Zimmermann M, Lottersberger F, Buonomo SB, Sfeir A, de Lange T. 2013. 53BP1 regulates DSB repair using Rif1 to control 59 end resection. Science 339: 700–704.